•  
  •  
  •  
  •  

2025-08-28 20:44:41

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
  • HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
  • Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
  • SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
  • Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
  • Lupin announces licensing deal for Ranibizumab Biosimilar
  • Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States
  • Lupin receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
  • Lupin receives Form 483 with 3 observations from USFDA for Pithampur Unit-3
  • Lupin achieves GMP Certification from TGA Australia for Dabhasa API Facility
  • Lupin receives Form 483 with 4 observations from USFDA for Pithampur Unit-2
  • Lupin launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States
  • Lupin receives approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
  • Lupin carves out LupinLife Consumer Healthcare
  • Lupin launches Prucalopride tablets in the United States
  • Lupin receives approval from U.S. FDA for Prucalopride Tablets
  • Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • Punita Lal Joins Lupin Board as Additional Director
  • Lupin receives approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg
  • Lupin Ltd recommends dividend of Rs. 12
  • Lupin Ltd posts consolidated PAT of Rs. 772.52 crores in Q4 FY2025
  • Lupin launches Eslicarbazepine Acetate Tablets in the United States
  • Lupin receives approval from U.S. FDA for Tolvaptan Tablets

Latest Post

  • Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
  • HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
  • Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
  • SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
  • Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024